Rinucumab

Edit links
Source: Wikipedia, the free encyclopedia.
Rinucumab
Monoclonal antibody
Type?
SourceHuman
Targetplatelet-derived growth factor receptor beta
Clinical data
Other namesREGN2176
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6472H9974N1710O2022S38
Molar mass145309.21 g·mol−1

Rinucumab (REGN2176) is a monoclonal antibody designed for the treatment of neovascular

age-related macular degeneration.[1][2]

This drug was developed by Regeneron Pharmaceuticals, Inc.

References

  1. ^ "Rinucumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
  2. S2CID 3505145
    .
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Rinucumab&oldid=1157645959"